Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Complex molecular and functional outcomes of single versus sequential cytokine stimulation of rat microglia.
Impact of Depression, Fatigue and Disability on Quality of Life in Chinese Patients with Multiple Sclerosis.
Characteristics of persons with overactive bladder of presumed neurologic origin: Results from the boston area community health (BACH) survey.
[Lyme disease in patients with multiple sclerosis: clinical, diagnostic and therapeutic features.]
White matter volume is decreased in the brain of patients with neuromyelitis optica.
Transcriptomic meta-analysis of multiple sclerosis and its experimental models.
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
FDA Approves First Drug for Lou Gehrig's Disease
MRI characteristics of familial and sporadic multiple sclerosis patients.
Regulation of encephalitogenicity of neuroantigen-primed T cells by nitric oxide: Implications for multiple sclerosis.
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain.
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study.
17β-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration.
CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.
Multiple sclerosis and stress.
Center for Drug Evaluation and Research Approval Letter, application number: 21-897
Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
New technologies for biomarker discovery in multiple sclerosis.
A culture system to study oligodendrocyte myelination processes using engineered nanofibers.
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Pages